SBIR/STTR Research Award
ALTERNATIVE SPLICING; A CHECKPOINT IN NEURODEGENERATION
Award amount
$99,948Program and phase
SBIR · Phase IAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MESSAGE PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Activation of apoptosis, specifically the
activation of caspases, leading to neuronal cell death may account for
neurodegeneration in Alzheimer's disease. Since caspase-2, an initiator
caspase, can act as a trigger to send a cell into apoptosis, its activity is
not only regulated at the protein level but also at the level of alternative
pre-mRNA splicing. Specific protein binding to an intronic sequence element, In
100, is critical for proper splice site usage. In 100 acts as a decoy acceptor
site that causes exon skipping. We propose to develop and validate reagents for
a high throughput assay that will be used to screen a compound library for
small molecules that will disrupt the specific protein binding to Ini 00. A
reporter gene will be added to a caspase-2 minigene construct to allow a
convenient and cost effective screening. The proper regulation of this
caspase-2 reporter minigene will be determined by comparison to the endogenous
gene assayed in the same cells. Cell lines expressing the caspase-2 minigenes
constructed in this Phase I application will be used to screen a small molecule
library in the Phase II study focused on the development of an
anti-neurodegenerative therapeutic.
Technology keywords
Not reported